800-680-1220 / +1 651-490-2860 (US) All locations

TSI.com (0)

Life Sciences

|

Software

Service

Contact

TSI.com
(0)

Menu

Ensuring Consistent and Precise Medication Delivery

Delivered Dose Uniformity (DDU)

Delivered Dose Uniformity (DDU) testing ensures that inhaler and nasal devices, such as pressurized metered-dose inhalers (pMDIs) and nebulizers, deliver the exact amount of medication needed by users. Whether it’s for life-critical situations or daily use, millions of people depend on these devices for consistent and precise drug delivery. DDU Testing ensures that each dose, from the first to the last, provides the correct amount of active pharmaceutical ingredient (API). This testing is essential to meet regulatory standards and maintain FDA approval, ensuring that the inhaler device performs reliably throughout its lifecycle.

Meeting Standards and Guidance for DDU

Inhaler devices must undergo rigorous testing to meet regulatory standards, often guided by USP <601>. To achieve and maintain FDA approval, the device must prove consistency, with no variation in dose delivery throughout its lifecycle or between capsules. Delivered dose is considered a Critical Quality Attribute (CQA), and detailed, proven method development is required to ensure consistent results across all worksites, analysts, and manufacturers.

Consistency of Dosage

DDU testing ensures that each dose delivered by an inhaler or nasal spray contains a uniform quantity of active pharmaceutical ingredients (API). Consistency across multiple doses is crucial to ensure patients receive the correct therapeutic dose every time. Variations in dose delivery can impact the efficacy of the treatment, making it important to monitor uniformity under various conditions, such as different orientations and flow rates.

Testing Across Device Lifespan

It’s important to conduct DDU testing throughout the lifecycle of the inhaler or nasal spray—starting from the first dose to the last. This includes testing devices when they are new, halfway used, and nearing the end of their usability to ensure that the device delivers a uniform dose throughout its entire lifespan. This helps to confirm reliability in real-world usage and ensures consistent patient outcomes.

OINDP Types

MDIs, DPIs and SMIs

DDU of Inhaler Devices

Delivered Dose Uniformity (DDU) testing for inhaler devices, such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs), ensures that each actuation delivers a consistent amount of medication. This is vital for maintaining therapeutic efficacy, as variations in dosage can lead to under- or over-dosing, affecting treatment outcomes. DDU testing evaluates the consistency of drug delivery across multiple doses, under various flow rates and conditions, simulating real-world usage. Ensuring uniformity across the device’s lifespan—from the first to the last dose—helps guarantee reliable and effective treatment for patients.

Frequently asked questions

Q. Why is DDU Testing important for inhaler devices?

DDU Testing guarantees that each dose from an inhaler device contains the correct amount of active pharmaceutical ingredient (API). This consistency is essential for patient safety, effective treatment, and regulatory compliance. Without DDU Testing, there could be variations in medication delivery, leading to ineffective treatment or potential harm to patients.

Q. What are the main challenges in DDU Testing for inhaler devices?

One of the main challenges in DDU Testing is ensuring that the device delivers a consistent dose across its entire lifecycle, including variations in storage conditions and user handling. Additionally, different types of inhalers, such as pMDIs, DPIs, and nebulizers, require specific testing setups and methodologies to accurately measure dose uniformity. --- Learn more here (link to resource talking about www.copleyscientific.com/inhaler-testing/delivered-dose-uniformity/)

Q. How is DDU Testing performed for different inhaler types?

DDU Testing varies by inhaler type. For pMDIs, the test flow rate is fixed, while DPIs require a critical flow controller to measure pressure drop and control flow conditions. Nebulizers are tested based on tidal breathing profiles to determine the total drug delivered during a treatment period. --- Learn more here (link to resource talking about www.copleyscientific.com/inhaler-testing/delivered-dose-uniformity/)

Calibrate Annually

Keep your Inhalation Pharmaceutical Testing Equipment in Compliance

Calibrate Annually

Keep your Inhalation Pharmaceutical Testing Equipment in Compliance

Annual calibration ensures inhaler testing equipment accuracy, reliability, and compliance. MSP offers comprehensive services, extending equipment lifespan and meeting regulatory standards.

Read More